Targets › H3F3A
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: the race on H3F3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| German Cancer Research Center | H3K27M peptide vaccine H3K27M neoepitope-specific peptide vaccine | H3F3A | Phase 1 | Newly Diagnosed H3-mutated Glioma | Nov 2026 |
Newly Diagnosed H3-mutated Glioma (1)
mixed (1)
German Cancer Research Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.